Fundraising Fox
/Companies
Sign in

VenoStent

YC S20

Houston, US · Founded 2017 · Delaware corporation · 17 employees · 16 known investors

Find your way into VenoStent

Sign up to see every warm intro you have to VenoStent

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the VenoStent team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

SelfWrap develops bioabsorbable wrap materials for vascular grafts that conform to individual patient anatomy and are designed to be absorbed by the body, unlike alloy-based alternatives. The company is developing the product for coronary and peripheral bypass grafting applications.

BiotechDigital HealthHealthtechMedical Devices3D PrintingUnited States of AmericaAmerica / Canada

Founders & leadership· Y Combinator alumni (S20)

VenoStent was founded in 2017 by Tim Boire and Geoffrey Lucks.

TBTim Boire
Tim BoireCo-founder · President and CEOTim Boire holds a BS in Chemical & Biological Engineering and Biotechnology from Tufts University and a PhD in Biomedical Engineering from Vanderbilt University, where he developed smart polymeric biomaterials for vascular applications. He worked in R&D at Genzyme Corporation before founding VenoStent, which applies these materials to hemodialysis access.
GLGeoffrey Lucks
Geoffrey LucksCOO and CofounderHe holds an MBA from Vanderbilt, a Master's degree in Bioethics from the University of Pennsylvania, and an undergraduate degree from the University of Wisconsin-Madison.

Board

JWJoel Whitley
Joel WhitleyBoard MemberPartner at IAG Capital Partners
JM
Jim MonsorBoard director
RCRobert Crutchfield
Robert CrutchfieldBoard directorOperating Partner at Good Growth Capital

Investors · 16

C3 Ventureslisted by C3 VenturesLos Angeles

How we know: C3 Ventures's portfolio page · Not right? Tell us

Cowtown Angelslisted by Cowtown AngelsFort Worth

How we know: Cowtown Angels's portfolio page · Y Combinator's founder network · Not right? Tell us

Creative Ventureslisted by Creative VenturesSan Francisco Bay Area · $1M

How we know: Creative Ventures's portfolio page · a partner's Signal profile · the VCSheet dataset · open dataset · 5k.vc investor directory · Y Combinator's founder network · Not right? Tell us

Good Growth Capitallisted by Good Growth CapitalCharleston

How we know: Good Growth Capital's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Y Combinator's founder network · Not right? Tell us

Health Wildcatterslisted by Health WildcattersDallas

How we know: Health Wildcatters's portfolio page · Y Combinator's founder network · Not right? Tell us

Kube VClisted by Kube VC
Norwest Venture Partnerslisted by Norwest Venture PartnersMenlo Park · $10M – $30M

How we know: open dataset · 5k.vc investor directory · Y Combinator's founder network · Not right? Tell us

Olima Ventureslisted by Olima VenturesWashington

How we know: Olima Ventures's portfolio page · Not right? Tell us

Texas HALO Fundlisted by Texas HALO FundHouston

How we know: Y Combinator's founder network · Not right? Tell us

TMC Venture Fundlisted by TMC Venture FundHouston

How we know: TMC Venture Fund's portfolio page · Y Combinator's founder network · Not right? Tell us

Wealthing VC Clublisted by Wealthing VC ClubPalo Alto

How we know: Wealthing VC Club's portfolio page · Not right? Tell us

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us

Cougar Venture FundreportedHouston

How we know: Y Combinator's founder network · Not right? Tell us

IAG Capital PartnersreportedCharleston

How we know: Y Combinator's founder network · Not right? Tell us

Skywalker InvestmentsreportedMadrid

How we know: Y Combinator's founder network · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$29.2M disclosed across 6 rounds · 2018–2026

▶$10MraisedMay 2026 · 29 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Geoffrey LucksExecutive Officer, Director
  • Joel WhitleyDirector
  • Timothy BoireExecutive Officer, Director
  • Jim MonsorDirector
  • Robert CrutchfieldDirector
Offering amount
$10M
Amount sold
$10M
Minimum investment
$10K
First sale
Apr 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.1MraisedJul 2023 · 60 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Joel WhitleyDirector
  • Timothy BoireExecutive Officer, Director
  • Jim MonsorDirector
  • Geoffrey LucksExecutive Officer, Director
  • Robert CrutchfieldDirector
Offering amount
$21.2M
Amount sold
$16.1M
First sale
Jul 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.2MraisedFeb 2021 · 24 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Timothy BoireExecutive Officer, Director
  • Kulika WeizmanDirector
  • Geoffrey LucksExecutive Officer, Director
Offering amount
$3M
Amount sold
$2.2M
First sale
Jan 2021
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$515KraisedJun 2020 · 16 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Geoffrey LucksExecutive Officer, Director
  • Timothy BoireExecutive Officer, Director
Offering amount
$535K
Amount sold
$515K
First sale
May 2020
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$263.9KraisedJul 2019 · 8 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Geoffrey LucksExecutive Officer, Director
  • Timothy BoireExecutive Officer, Director
Offering amount
$300K
Amount sold
$263.9K
Minimum investment
$10K
First sale
Jun 2019
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$70KraisedMar 2018 · 4 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Geoffrey LucksExecutive Officer, Director
  • Timothy BoireExecutive Officer, Director
Offering amount
$400K
Amount sold
$70K
First sale
Mar 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

3 people who came through VenoStent went on to found or lead other companies.

Alex SmithSenior Product Engineer ConsultantFounded TYBR Health +2Kulika WeizmanBoard ObserverFounded SugarlogixMichael NagelMember Board Of DirectorsFounded Raydiant Oxymetry

Related companies · 10

ArchFormArchForm provides clear aligner devices for orthodontic treatment, offering customers cost savings compared to alternative aligner companies.
BDBD is a global medical technology company developing devices, systems, and solutions for medication administration, diagnostics, connected care, biopharmaceutical manufacturing, and interventional procedures. The company serves healthcare providers, laboratories, and biopharmaceutical manufacturers across diagnostics, drug delivery, surgical care, and patient monitoring.
Voodoo ManufacturingVoodoo Manufacturing operates a high-volume 3D printing factory producing plastic parts at scale, alongside offering 3D design services including CAD design to convert concepts into manufacturable files. The company serves manufacturers, designers, and businesses of all sizes needing digital manufacturing from prototyping to production.
SinterSinter operates a US-based plastics manufacturing pipeline using additive technologies, helping hardware teams move from 3D-printed prototypes to production parts on week-scale timelines.
Venova MedicalVenova Medical develops the Velocity percutaneous arteriovenous fistula system, a minimally invasive medical device designed to create vascular access for hemodialysis patients more efficiently than traditional surgical methods. The system addresses barriers to AVF creation and maturation, targeting patients with chronic kidney disease who require dialysis access.
Relativity SpaceRelativity Space develops Terran R, a reusable medium-to-heavy-lift rocket designed for efficiency and scalability, serving government entities, telecommunications companies, and commercial customers for space access missions. The company focuses on making space exploration more accessible, reliable, and sustainable.
Boston ScientificBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
Vantis VascularVantis Vascular develops vascular intervention technology, including the CrossFast integrated vascular delivery system with an auto-locking inner monorail microcatheter and outer delivery catheter for complex PCI procedures. Founded by physicians, the company is also developing next-generation intravascular lithotripsy (IVL) and peripheral below-the-knee (BTK) solutions for vascular interventionalists.</parameter> <parameter name="founders">[{"full_name": "Jason Turner", "title": "Chief Executive Officer"}, {"full_name": "Tim Fischell", "title": "Chief Medical Officer"}, {"full_name": "Frank Saltiel", "title": "Chief Clinical Officer"}, {"full_name": "Gary McCord", "title": "Chief Commercial Officer"}, {"full_name": "Mike Mirizzi", "title": "Chief Technology Officer"}, {"full_name": "Marc Monahan", "title": "Chief Financial Officer"}]</parameter> <parameter name="hq_city">San Jose
Intervene IncInterVene, Inc. is a medical device company that has developed a fully integrated mechanical thrombectomy system to treat venous in-stent restenosis and residual thrombotic venous obstructions and occlusions. Its technology targets venous disease conditions such as postthrombotic syndrome that current therapies fail to address.
Innova VascularInnova Vascular is a medical device company focused on the vascular space, led by a founder with a background in developing and commercializing vascular medical devices. The page provides limited detail about the company's specific products.

Companies working in the same space as VenoStent.

Non-dilutive funding · 3 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2020$299.9K
National Science FoundationPhase II2019$744.2K
National Science FoundationPhase ISTTR2018$224.5K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Legal entities · 1

corporate structure
VenoStent, Inc.

In the news

VenoStent Completes $16M Series A Financing, Receives IDE Approval from FDA to Begin US Trialfinance.yahoo.com · Jul 2023

Frequently asked questions

What does VenoStent do?
SelfWrap develops bioabsorbable wrap materials for vascular grafts that conform to individual patient anatomy and are designed to be absorbed by the body, unlike alloy-based alternatives. The company is developing the product for coronary and peripheral bypass grafting applications.
Who founded VenoStent?
VenoStent was founded by Tim Boire, Geoffrey Lucks in 2017.
Who are VenoStent's investors?
VenoStent's investors include Alumni Ventures, C3 Ventures, Cowtown Angels, Creative Ventures, Good Growth Capital, Health Wildcatters, Kube VC, Norwest Venture Partners and 8 more.
How much funding has VenoStent raised?
VenoStent has disclosed $29.2M raised across 6 rounds.
Where is VenoStent headquartered?
VenoStent is headquartered in Houston, US.